Filtered By:
Specialty: Cancer & Oncology
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 846 results found since Jan 2013.
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Clinical Breast Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Identification of a TRP channel-related risk model for predicting prognosis and therapeutic effects of patients with hepatocellular carcinoma
CONCLUSIONS: We successfully established a highly accurate prognostic model for predicting overall survival and therapeutic effects using TRP channel-related genes.PMID:37733242 | DOI:10.1007/s00432-023-05394-7
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Chong Pang Zhe Xu Jilong Han Fujun Li Hongyan Zhu Jiaqi Zhang Dong Wang Xundi Xu Source Type: research
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
CONCLUSIONS: Cumulatively, these results support the combination of ramucirumab plus docetaxel as an effective and safe subsequent therapy for the treatment of patients with metastatic NSCLC with disease progression irrespective of previous ICI treatment.PMID:37731641 | PMC:PMC10507469 | DOI:10.3389/fonc.2023.1247879
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Edward B Garon Carla Visseren-Grul Maria Teresa Rizzo Tarun Puri Suresh Chenji Martin Reck Source Type: research
Identification of a TRP channel-related risk model for predicting prognosis and therapeutic effects of patients with hepatocellular carcinoma
CONCLUSIONS: We successfully established a highly accurate prognostic model for predicting overall survival and therapeutic effects using TRP channel-related genes.PMID:37733242 | DOI:10.1007/s00432-023-05394-7
Source: Clinical Genitourinary Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Chong Pang Zhe Xu Jilong Han Fujun Li Hongyan Zhu Jiaqi Zhang Dong Wang Xundi Xu Source Type: research
Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study
CONCLUSIONS: An increasing proportion of patients received systemic treatment during the period 2010-18. However, less than 50% of patients in our study received systemic treatment. In accordance with updated guidelines, Docetaxel was introduced after 2015 with an increasing proportion of patients receiving systemic treatment as mHSPC. Further studies should address the disease course and treatment given to patients who do not receive systemic treatment.PMID:37725527 | DOI:10.1080/0284186X.2023.2257876
Source: Acta Oncologica - September 19, 2023 Category: Cancer & Oncology Authors: Anne Holck Stor ås Kaitlyn Tsuruda Sophie Dorothea Foss å Bettina Kulle Andreassen Source Type: research
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
CONCLUSION: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.PMID:37725049 | DOI:10.1093/oncolo/oyad258
Source: The Oncologist - September 19, 2023 Category: Cancer & Oncology Authors: Juan Luis Gomez Marti Azadeh Nasrazadani Ying Ding Daniel Normolle Adam M Brufsky Source Type: research
Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study
CONCLUSIONS: An increasing proportion of patients received systemic treatment during the period 2010-18. However, less than 50% of patients in our study received systemic treatment. In accordance with updated guidelines, Docetaxel was introduced after 2015 with an increasing proportion of patients receiving systemic treatment as mHSPC. Further studies should address the disease course and treatment given to patients who do not receive systemic treatment.PMID:37725527 | DOI:10.1080/0284186X.2023.2257876
Source: Acta Oncologica - September 19, 2023 Category: Cancer & Oncology Authors: Anne Holck Stor ås Kaitlyn Tsuruda Sophie Dorothea Foss å Bettina Kulle Andreassen Source Type: research
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
CONCLUSION: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.PMID:37725049 | DOI:10.1093/oncolo/oyad258
Source: The Oncologist - September 19, 2023 Category: Cancer & Oncology Authors: Juan Luis Gomez Marti Azadeh Nasrazadani Ying Ding Daniel Normolle Adam M Brufsky Source Type: research
In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
Conclusions TNBC is a difficult-to-treat oncologic condition, even in an experimental setting. Promising results concerning the addition of targeted therapies (dasatinib) to the conventional cytotoxic ones (docetaxel) have been shown, awaiting further evaluation.PMID:37719631 | PMC:PMC10500968 | DOI:10.7759/cureus.43534
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Ioannis D Passos Dimochristos Papadimitriou Areti Katsouda Georgios E Papavasileiou Apostolos Galatas Panagiotis Tzitzis Alexandra Mpakosi Maria Mironidou-Tzouveleki Source Type: research
Ki67 and prostate specific antigen are prognostic in metastatic hormone na ïve prostate cancer
CONCLUSION: PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.PMID:37713321 | DOI:10.1080/0284186X.2023.2254480
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: Vasiliki Spyratou Eva Freyhult Anders Bergh Camilla Thellenberg-Karlsson Pernilla Wikstr öm Karin Wel én Andreas Josefsson Source Type: research
